JP2011500718A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500718A5
JP2011500718A5 JP2010530124A JP2010530124A JP2011500718A5 JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5 JP 2010530124 A JP2010530124 A JP 2010530124A JP 2010530124 A JP2010530124 A JP 2010530124A JP 2011500718 A5 JP2011500718 A5 JP 2011500718A5
Authority
JP
Japan
Prior art keywords
mva
antigen
polypeptide
pap
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500718A (ja
JP5669581B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/080229 external-priority patent/WO2009052328A1/en
Publication of JP2011500718A publication Critical patent/JP2011500718A/ja
Publication of JP2011500718A5 publication Critical patent/JP2011500718A5/ja
Application granted granted Critical
Publication of JP5669581B2 publication Critical patent/JP5669581B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530124A 2007-10-18 2008-10-16 前立腺癌を処置するためのmvaの使用 Expired - Fee Related JP5669581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96089307P 2007-10-18 2007-10-18
US60/960,893 2007-10-18
PCT/US2008/080229 WO2009052328A1 (en) 2007-10-18 2008-10-16 Use of mva to treat prostate cancer

Publications (3)

Publication Number Publication Date
JP2011500718A JP2011500718A (ja) 2011-01-06
JP2011500718A5 true JP2011500718A5 (enExample) 2011-10-20
JP5669581B2 JP5669581B2 (ja) 2015-02-12

Family

ID=40342626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530124A Expired - Fee Related JP5669581B2 (ja) 2007-10-18 2008-10-16 前立腺癌を処置するためのmvaの使用

Country Status (13)

Country Link
US (2) US7867483B2 (enExample)
EP (1) EP2207564B1 (enExample)
JP (1) JP5669581B2 (enExample)
KR (2) KR20160065985A (enExample)
CN (1) CN101888853B (enExample)
AU (1) AU2008312444B2 (enExample)
CA (1) CA2702586C (enExample)
DK (1) DK2207564T3 (enExample)
ES (1) ES2608604T3 (enExample)
IL (1) IL204541A (enExample)
NZ (2) NZ584042A (enExample)
RU (1) RU2499606C2 (enExample)
WO (1) WO2009052328A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
KR100910297B1 (ko) * 2000-11-23 2009-08-03 버베리안 노딕 에이/에스 변형된 백시니아 앙카라 바이러스 변형체
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
NZ584042A (en) * 2007-10-18 2012-09-28 Bn Immunotherapeutics Inc Use of mva to treat prostate cancer
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
US10517969B2 (en) * 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
US8772459B2 (en) 2009-12-02 2014-07-08 Imaginab, Inc. J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
WO2013146997A1 (ja) 2012-03-30 2013-10-03 国立大学法人京都大学 前立腺がん検査用尿中バイオマーカー
PE20171142A1 (es) 2013-11-01 2017-08-10 Pfizer Vectores para expresion de antigenos asociados a prostata
MX2017003640A (es) 2014-09-19 2017-10-31 Regeneron Pharma Receptores antigenicos quimericos.
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
NZ739721A (en) 2015-08-07 2019-09-27 Imaginab Inc Antigen binding constructs to target molecules
WO2017054832A1 (en) * 2015-10-02 2017-04-06 University Of Copenhagen Small molecules blocking histone reader domains
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
CN108883203A (zh) 2016-02-12 2018-11-23 麦迪逊疫苗公司 癌症疗法
SG11201807051VA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
BR112018016948A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
US10703755B2 (en) * 2016-04-26 2020-07-07 Sumitomo Dainippon Pharma Co., Ltd. Substituted purine derivative
JP6983819B2 (ja) * 2016-06-03 2021-12-17 エトゥビクス コーポレーション 前立腺がん関連抗原を使用する腫瘍ワクチン接種用の組成物及び方法
PT4218408T (pt) 2016-06-03 2025-03-26 Regeneron Pharma Roedores que expressam desoxinucleotidil-transferase terminal exógena
CN106084027A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 特异性肿瘤抗原EphA2的CTL识别表位肽及其应用
CN106119231A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种肿瘤抗原psa的ctl识别表位肽及其应用
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center USEFUL VACCINE VIRUS MUTANTS FOR ANTI-CANCER IMMUNOTHERAPY
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN114206385A (zh) * 2019-06-07 2022-03-18 俄勒冈健康与科学大学 肿瘤相关抗原特异性t细胞应答
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
JP2023521194A (ja) * 2020-04-13 2023-05-23 ヤンセン バイオテツク,インコーポレーテツド Psma及びsteap1ワクチン並びにそれらの使用
US12295997B2 (en) * 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100198868B1 (ko) * 1991-07-25 1999-06-15 케네쓰 제이. 울코트 세포독성 t 림프구 반응을 유도하는 조성물
ES2245778T3 (es) * 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
WO1998004689A1 (en) * 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
EP0973916A1 (en) * 1997-04-11 2000-01-26 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
CN1325115C (zh) * 1998-10-05 2007-07-11 法麦克萨有限公司 Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用
PT1137792E (pt) * 1998-12-09 2007-08-10 Therion Biolog Corp Vector recombinado que exprime moléculas costimulantes múltiplas e as suas utilizações
KR100910297B1 (ko) * 2000-11-23 2009-08-03 버베리안 노딕 에이/에스 변형된 백시니아 앙카라 바이러스 변형체
US7718166B2 (en) * 2002-03-01 2010-05-18 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille Calmette-Guerin expressing prostate specific antigens
NZ536501A (en) * 2002-05-16 2006-08-31 Bavarian Nordic As Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
AU2004267117B2 (en) * 2003-08-21 2011-01-20 Virax Development Pty Ltd Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
BRPI0401465A (pt) 2004-04-20 2006-02-21 Embria Informatica Ltda sistema para administrar interações entre usuários e aplicações de software em um ambiente web
NZ584042A (en) * 2007-10-18 2012-09-28 Bn Immunotherapeutics Inc Use of mva to treat prostate cancer

Similar Documents

Publication Publication Date Title
JP2011500718A5 (enExample)
Moore et al. Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria
Verardi et al. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication
Guse et al. Oncolytic vaccinia virus for the treatment of cancer
EP2958994B1 (en) Vaccine composition
US9707285B2 (en) Vaccination methods
RU2010115220A (ru) Применение mva (модифицированный вирус коровьей оспы анкара) для лечения рака простаты
Webster et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
Wilck et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration
WO2015106697A1 (zh) 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
JP2024105526A (ja) 免疫応答を誘導するための組成物
US8734806B2 (en) Immunogenic composition and use thereof
JP2018517419A5 (enExample)
Bubenik et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
JP2020511139A5 (enExample)
RU2018101722A (ru) Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
JP2014139185A5 (enExample)
Chen et al. Optimisation of prime–boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine
Beilvert et al. DNA/amphiphilic block copolymer nanospheres reduce asthmatic response in a mouse model of allergic asthma
Marcos-Villar et al. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium
RU2019125436A (ru) Новый подход к иммунотерапии, нацеленной на vegfr-2
Ren et al. Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination
JP7454320B2 (ja) アジュバントとしての腫瘍溶解性ウイルス
Yang et al. Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity